Algorithm Proposed to Expand Cisplatin Eligibility for MIBC
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Bone Cancer
BONE CANCER ADVISOR
FEATURED CONTENT
-
-
Fact Sheet: COVID-19 Vaccine Considerations for Patients With Cancer
This fact sheet reviews the current guidelines for coronavirus disease 2019 (COVID-19) vaccination in patients with cancer. -
Bariatric Surgery and Colorectal Cancer: Is There a Risk?
C. Andrew Kistler, MD, PharmD, examines existing data about bariatric surgery and the risk for subsequent colorectal cancer development. -
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC). -
Do Early-Generation TKIs Still Have a Place in EGFR exon 19 or exon 21 L858R-Mutated NSCLC?
A recent wave of approvals has transformed the treatment landscape in non-small cell lung cancer with the most common EGFR mutations— EGFR exon 19 or exon 21 L858R- substitution mutations—giving clinicians a choice between 6 different interventions in the metastatic setting.
BONE CANCER NEWS
Crysvita Approved for Treatment of Tumor-Induced Osteomalacia
Strontium89 Now Available for Relief of Metastatic Bone Pain
FDA Grants Orphan Drug Designation to BN-Brachyury for Chordoma
CTA Treatment Regimen Chart for Bone Cancer Updated
Baseline EFS Outcomes Identified for Recurrent/Refractory Pediatric Osteosarcoma
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
